Nakagawa Yukinori, Ikeda Uichi, Hirose Masahiro, Ubukata Satoshi, Katsuki Taka-Aki, Kaminishi Yuichiro, Saito Tsutomu, Hironaka Mitsugu, Izumi Tohru, Shimada Kazuyuki
Division of Cardiovascular Medicine, Jichi Medical School, Tochigi, Japan.
Circ J. 2004 Feb;68(2):172-3. doi: 10.1253/circj.68.172.
Primary cardiac malignant lymphoma is extremely rare and almost all patients die within weeks. Monoclonal CD20 antibody (rituximab) was administered to a patient with primary cardiac B-cell non-Hodgkin's lymphoma expressing a CD20 molecule. The results suggest that rituximab may be a safe and effective new therapy for primary cardiac B-cell lymphoma.
原发性心脏恶性淋巴瘤极为罕见，几乎所有患者都会在数周内死亡。一名表达CD20分子的原发性心脏B细胞非霍奇金淋巴瘤患者接受了单克隆CD20抗体（利妥昔单抗）治疗。结果表明，利妥昔单抗可能是治疗原发性心脏B细胞淋巴瘤的一种安全有效的新疗法。
